On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to ...

Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million following its bankruptcy filing due to declining demand ...

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and ...

The consumer-genomics company 23andMe just sold its biobank of customer genetic data to drugmaker Regeneron for $256 million.

After acquiring 23andMe, Regeneron Pharmaceuticals has said it will protect user data as it uses DNA data for drug ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

South San Francisco, California-based 23andMe filed for bankruptcy last month, seeking to sell its business at auction after ...